Mentioned in Fortune 40 under 40 in 2017, Mr Eltoukhy is a serial entrepreneur and pioneer in the biotech industry. He joined the Stanford Genome Technology Center (SGTC) in 2006 to work on low-cost DNA sequencing technologies.
His company Guardant health aims to change the way biopsies are carried out in the medical industry. Their ‘liquid biopsy’ technology makes it easier to spot cancer markers in the blood samples. As founding Chief Executive Officer, he led Guardant through two rounds of financing and through acquisition by Illumina in 2008.
At Illumina, Mr Eltoukhy was Sr. Director of Advanced Technology Research, where he developed novel chemistries, hardware and informatics for genetic analysis systems. He received his PhD, MS and BS degrees in electrical engineering from Stanford University.